Guiling Li - Concepedia

Author

Guiling Li

Obstetrics and Gynecology Hospital of Fudan University ORCID

Also Known As

G Li, GUILING LI, Gui-Ling Li, Gui-ling Li, Guiling Li

Publications

Citations

H-Index

Concepts

All Affiliations

Obstetrics and Gynecology Hospital of Fudan University Huazhong University of Science and Technology Hunan Cancer Hospital Union Hospital Hubei Cancer Hospital

About

Guiling Li is an author at Obstetrics and Gynecology Hospital of Fudan University specializing in medicine, immunotherapy, and cervical cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	567
2	Immunology	4	4	144
3	Cell Biology	2	2	44
4	Health Sciences	1	1	73
5	Public Health	1	1	130

Guiling Li

Publications

831

Citations

H-Index

Page 1

	Year	Citations
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial Xiangyu Gao, Nong Xu, Ziyu Li, The Lancet Oncology OncologyMedicineAdvanced Solid TumoursImmune Checkpoint InhibitorAnti-cancer Agent	2023	171
Ovarian Masses in Children and Adolescents - An Analysis of 521 Clinical Cases Mingxing Zhang, Wei Jiang, Guiling Li, Journal of Pediatric and Adolescent Gynecology InfertilityGynecological SurgeryOvarian MassesPediatric GynecologyReproductive Health	2013	130
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China Xiaohua Wu, Yang Sun, Hongying Yang, The Lancet Metastatic Cervical CancerCervical CancerPlacebo-controlled Phase 3MedicineClinical Trials	2024	73
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075) Xiaohua Wu, Jiafu Ji, Hanmei Lou, Gynecologic Oncology Cervical CancerPhase Ii TrialMedicineImmunologyPathology	2022	60
Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer Yumeng Wang, Congwen Wang, Junjun Qiu, Journal for ImmunoTherapy of Cancer	2022	59
HPV E6 down-regulation and apoptosis induction of human cervical cancer cells by a novel lipid-soluble extract (PE) from Pinellia pedatisecta Schott in vitro Guiling Li, Wei Jiang, Qing Xia, Journal of Ethnopharmacology Cervical CancerApoptosis InductionHuman Papillomavirus VaccinesMedicineCell Death	2010	49
A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC). Jing Wang, Hanmei Lou, Hongbing Cai, Journal of Clinical Oncology Metastatic Cervical CancerCervical CancerAk104 MonotherapyR/m CcAnti-ctla4 Bispecific Antibody	2022	40
Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism Meng Zhang, Qiyu Liu, Mingxing Zhang, Journal of Nanobiotechnology	2020	35
A novel ferroptosis-related gene signature for predicting outcomes in cervical cancer Xingling Qi, Yi‐Peng Fu, Jia Sheng, Bioengineered	2021	34
Clinical analysis of uterine intravenous leiomyomatosis: A retrospective study of 260 cases Jing Peng, Fangfang Zhong, Yuemeng Zhu, Journal of obstetrics and gynaecology research	2021	26

Page 1